Evidence map›Paper›PMID 32157214›Full record

ArticleOncogene2020

Identification of Sca-1

Huijing Yin, Zhengyu Jiang, Xu Feng, Zhaodong Ji, Wei Jin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Huijing Yin *Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. yinhuijing@fudan.edu.cn.
Zhengyu Jiang *Department of Anesthesiology, Naval Medical Center, Naval Medical University/Second Military Medical University, PLA, Shanghai, 200052, China.
Xu FengCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zhaodong JiCancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Wei JinDepartment of Immunology and Microbiology, Shanghai Institute of Immunology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Fudan University Shanghai Cancer Center · CNSecond Military Medical University · CNShanghai Jiao Tong University · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The reason for the reduced efficacy of lung cancer therapy is the existence of lung cancer stem cells (CSCs). Targeting CSCs results in evolved phenotypes with increased malignancy, leading to therapy failure. Here, we propose a new therapeutic strategy: investigating the "transitional" cells that represent the stage between normal lung stem cells and lung CSCs. Identifying and targeting the key molecule that drives carcinogenesis to inhibit or reverse this process would thus provide new perspectives for early diagnosis and intervention in lung cancer. We used Gprc5a-knockout (KO) mice, the first animal model of spontaneous lung adenocarcinoma established by the deletion of a single lung tumor suppressor gene. We investigated the interaction of lung progenitor cells AT2 with Lgr5 cells in the generation of CSCs and related signaling mechanism. In the present study, using Gprc5a-KO mice, we found the initiator Sca-1

Indexed as

Adenocarcinoma of LungAnimalsAntigens, LyATP Binding Cassette Transporter, Subfamily G, Member 1CarcinogenesisCell LineageCell Line, TumorCoculture TechniquesDisease Models, AnimalEpithelial CellsHumansMembrane ProteinsMiceMice, KnockoutNeoplastic Stem CellsPneumoniaABCG1 protein, mouseAntigens, LyATP Binding Cassette Transporter, Subfamily G, Member 1GPRC5A protein, mouseLy6a protein, mouseMembrane ProteinsReceptors, G-Protein-Coupled

Identifiers

PMID32157214
PMCPMC7190569
OpenAlexW3011197006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.